Emerging Strategies in Neuroprotection

  • Paul J. Marangos
  • Harbans Lal

Part of the Advances in Neuroprotection book series (AN, volume 22)

Table of contents

  1. Front Matter
    Pages i-xix
  2. Preclinical Ischemia Model Systems

    1. Front Matter
      Pages 1-1
    2. Heike Oberpichler-Schwenk, Josef Krieglstein
      Pages 3-23
    3. Avital Schurr, Benjamin M. Rigor
      Pages 24-43
    4. Chung Y. Hsu, Yong Y. He, Teng N. Lin, Grace Wu, Paul J. Marangos
      Pages 44-56
    5. Justin A. Zivin
      Pages 57-75
    6. Ronald L. Hayes, C. Edward Dixon, Susan R. Carrin
      Pages 76-89
  3. Neuroprotective Approaches in Stroke and Head Trauma

    1. Front Matter
      Pages 91-91
    2. Dirk Sauer, Lourdes Massieu, Peter R. Allegrini, Hugo Amacker, Markus Schmutz, Graham E. Fagg
      Pages 93-105
    3. Brian Meldrum
      Pages 106-128
    4. Giora Feuerstein, Jackie Hunter, Frank C. Barone
      Pages 129-150
    5. K. J. Dag, E. von Lubitz, Paul J. Marangos
      Pages 151-186
    6. Sahebarao P. Mahadik
      Pages 187-223
    7. Mordecai Y.-T. Globus, Raul Busto, W. Dalton Dietrich, Linda Sternau, Eiharu Morikawa, Myron D. Ginsberg
      Pages 289-306
  4. Clinical Endpoints for Neuroprotective Drugs

    1. Front Matter
      Pages 307-307
    2. Richard C. Meibach
      Pages 309-325
    3. Charles F. Zorumski, John W. Olney
      Pages 326-343
  5. Back Matter
    Pages 345-359

About this book


SOLOMON H. SNYDER Receptor Research Reaches Neurology: Relevance to Neurodegenerative Diseases and Stroke President George Bush has heralded the 1990s as the decade of the brain, based largely on the rapid escalation of advances in the molecular neuro­ sciences and the likelihood that these will bear therapeutic fruit before the turn of the century. There is little doubt that the 1970s and 1980s have witnessed more remarkable advances in the molecular neurosciences than all of the preceding hundred years. Identification of receptor sites for drugs and neurotransmitters along with simple, sensitive, and specific means of monitoring them has made it possible to elucidate the mechanism of action for many known drugs and to identify new chemical entities as potential therapeutic agents. At the same time, the numbers of distinct neurotrans­ mitters have multiplied. Prior to 1970 only the biogenic amines were well accepted as transmitters. The early 1970s witnessed the gradual acceptance of amino acids as major excitatory and inhibitory neurotransmitters. Identification of opiate receptors and the subsequent identification of the enkephalins as their endogenous ligands led to an appreciation of peptides as putative transmitters and the accumulation of as many as a hundred neuropeptides by the decade's end. In the 1980s the revolutions of molecular biology have been applied aggressively to the neurosciences with molecular cloning for neuropeptide precursors, many important neurochemical en­ zymes, and receptors for numerous transmitters.


Evolution biology brain neuroscience receptor

Editors and affiliations

  • Paul J. Marangos
    • 1
  • Harbans Lal
    • 2
  1. 1.NeuroTherapeutics Corp. and Center for Neurologic StudySan DiegoUSA
  2. 2.Department of PharmacologyTexas College of Osteopathic MedicineFort WorthUSA

Bibliographic information